Reishi, ashwagandha and rhodiola gummies: what to know

The term adaptogen was formalised by Soviet pharmacologists in the 1950s to describe substances supposed to help the body better withstand stress. The concept remains scientifically debated and is not recognised by European health authorities as a validated therapeutic mechanism. Three plants come up repeatedly in "stress support" supplements: reishi (Ganoderma lucidum), a mushroom used in Chinese pharmacopoeia; ashwagandha (Withania somnifera), an Indian shrub from Ayurveda; and rhodiola (Rhodiola rosea), a plant of Arctic regions.

Plant-based food supplements fall under decree no. 2006-352, which transposes directive 2002/46/EC. In its opinion 2022-SA-0085 on ashwagandha, ANSES recorded reports of adverse effects, notably on the liver, and recommended vigilance over the quality of preparations and the identification of at-risk groups. No health claim within the meaning of EC regulation 1924/2006 is authorised for these plants: commercial wording remains a matter of composition, never a promise of effect.

Reishi contains triterpenes, polysaccharides and beta-glucans. A scoping review published in 2022 gathered preliminary findings on fatigue in certain clinical populations, without reaching a level of evidence sufficient for a medical recommendation. Common supplement doses range from 200 to 500 mg of extract per day.

Ashwagandha is the most studied plant of the three: several clinical trials, including Lopresti et al. (2019, Medicine), have examined its effect on stress markers at doses of 240 to 600 mg of standardised extract per day. ANSES has called for caution given the risks of drug interactions and the adverse liver effects reported.

Rhodiola roots contain salidrosides and rosavins. Several exploratory studies have looked at its role in cognitive fatigue, with common doses of 170 to 600 mg of extract per day, in clinical trials of broadly average methodological quality.

A serious supplement states the part used (the reishi fruiting body is more concentrated in triterpenes than cultivated mycelium), a standardised titration, an independent certificate of analysis and a traceable origin. Three precautions apply to all three plants: they are not advised during pregnancy and breastfeeding, they call for checking that there is no interaction with current treatments (anticoagulants, sedatives, immunosuppressants, thyroid hormones), and they mean avoiding the stacking of several sources of the same extract.

Some brands combine CBD and adaptogens in a single product. CBD falls under a specific regime set by the Conseil d'État decision of 29 December 2022, and since 15 May 2026 CBD food products without Novel Food authorisation have been withdrawn from the French market. Our article on CBD and occasional stress sets out that specific framework.

CBD is not a medicine. If anxiety persists, consult a healthcare professional.

Are reishi gummies reimbursed in France?

No. They are food supplements sold over the counter, with no cover from the health insurance system.

Can ashwagandha be combined with an antidepressant treatment?

Not without medical advice. Several interactions are described with serotonergic drugs and sedatives. Consulting your doctor or pharmacist is essential before any such combination.

How long before an effect is felt?

No claim of effect is legally permitted. Regular users often describe a perceived change after two to six weeks of continuous use, as a matter of personal wellbeing.

Is there a maximum recommended dose?

The doses stated on the packaging must be observed. ANSES recommends not stacking several sources of the same extract, such as gummies and capsules, at the risk of exceeding the levels studied.